Business Context and Reporting Period
Company: Pluristem Therapeutics Inc. (PSTI)
Filing Type: Form 8-K (Current Report)
Reporting Date: July 25, 2019 (Event Date: July 23, 2019)
Context: The Company filed a Certificate of Change with the State of Nevada to effect a 1-for-10 reverse stock split of its authorized and outstanding common and preferred stock. The split became effective on July 25, 2019.
Key Financial Metrics
This filing is a corporate action report and does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The filing text does not provide a clear value for these metrics.
Material Changes Versus Prior Period
- Capitalization Adjustment: Authorized common stock reduced from 300,000,000 to 30,000,000 shares.
- Outstanding Shares: Reduced from approximately 153,122,520 shares (as of July 24, 2019) to approximately 15,312,252 shares post-split.
- Preferred Stock: Authorized preferred stock reduced from 10,000,000 to 1,000,000 shares. No preferred stock was issued or outstanding.
- Trading Details: The stock continues to trade on the Nasdaq Capital Market under the symbol "PSTI" but with a new CUSIP Number (72940R300).
- Ownership: Shareholder percentage ownership and voting power remain virtually unchanged, subject to minor rounding adjustments.
Guidance, Outlook, and Unusual Items
Management Commentary: The Board of Directors approved the reverse split under Nevada Revised Statutes Section 78.207, which did not require shareholder approval. The action was taken to proportionally reduce authorized and outstanding shares without adversely affecting other stock classes.
Unusual Items / Mechanics:
- Fractional Shares: No fractional shares or cash payments were issued. Shareholders entitled to fractional shares received one additional whole share.
- Derivatives Adjustment: All outstanding options, warrants, and convertible securities were adjusted by dividing the share count by 10 and multiplying the exercise/conversion price by 10.
Risks and Contingencies: The filing does not disclose new material risks or contingencies beyond the standard execution of the corporate action.
Investor Verification Checklist
- Verify the new CUSIP Number (72940R300) for trading and settlement purposes.
- Confirm the adjusted number of shares held in brokerage accounts reflects the 1-for-10 ratio and rounding rules.
- Review the adjusted exercise prices and share quantities for any outstanding options or warrants.
- Monitor the post-split trading volume and price stability on the Nasdaq Capital Market.